Concourse Financial Group Securities’s Pacira BioSciences PCRX Stock Holding History

Concourse Financial Group Securities’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-17	Closed	-$291	–	2348
2024 Q2	$486	Sell	17 -4	-19%	-$114	﹤0.01%	2202
2024 Q1	$613	Buy	21 +11	+110%	+$338	﹤0.01%	2196
2023 Q4	$337	Hold	10	–	–	﹤0.01%	2217
2023 Q3	$306	Sell	10 -4	-29%	-$144	﹤0.01%	2226
2023 Q2	$560	Buy	14 +3	+27%	+$124	﹤0.01%	2217
2023 Q1	$448	Buy	+11	New	+$438	﹤0.01%	2257
2022 Q4	–	Sell	-15	Closed	-$730	–	2340
2022 Q3	$1K	Sell	15 -847	-98%	-$47.1K	﹤0.01%	1913
2022 Q2	$50K	Sell	862 -894	-51%	-$58.6K	﹤0.01%	1079
2022 Q1	$134K	Buy	+1,756	New	+$117K	0.01%	763
2019 Q4	–	Sell	-47	Closed	-$2K	–	2112
2019 Q3	$2K	Hold	47	–	–	﹤0.01%	1557
2019 Q2	$2K	Hold	47	–	–	﹤0.01%	2018
2019 Q1	$1K	Sell	47 -48	-51%	-$1.87K	﹤0.01%	2170
2018 Q4	$4K	Buy	+95	New	+$4.43K	﹤0.01%	1754

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Concourse Financial Group Securities's PCRX Position: Q3 2024 in Review

Concourse Financial Group Securities sold out of Pacira BioSciences (PCRX) in Q3 2024, closing a stake of 17 shares — an estimated $291 sold.

Concourse Financial Group Securities first reported a position in PCRX in Q4 2018 and held it in 13 quarters. The position peaked at $134K in Q1 2022. 239 funds tracked by Wall St. Rank hold PCRX as of Q3 2024.

Concourse Financial Group Securities reported no remaining Pacira BioSciences position as of Q3 2024 after selling out during the quarter.
Concourse Financial Group Securities sold 17 Pacira BioSciences shares in Q3 2024, an estimated $291.
Concourse Financial Group Securities first reported a position in Pacira BioSciences in Q4 2018 and held it in 13 quarters.
Concourse Financial Group Securities's Pacira BioSciences position peaked at $134K in Q1 2022.
239 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2024.

Based on Concourse Financial Group Securities's 13F filing for Q3 2024, filed 10 Oct 2024.